Tenax Therapeutics
Quarterly Financials
| Values in thousands | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -17,728 | -18,784 | -15,716 | -15,540 |
EBIT | -17,728 | -18,784 | -16,573 | -15,540 |
Net Income | -16,704 | -17,803 | -15,716 | -15,540 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -12,479 | -14,150 | -9,309 | -13,415 |
Cash | 113,729 | 117,976 | 118,755 | 97,565 |
Basic Shares | 53,452 | 50,869 | 45,226 | 39,217 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -7 | -113 | ||
EBITDA | -52,599 | -17,579 | -7,679 | -10,930 |
EBIT | -52,599 | -17,625 | -7,687 | -11,043 |
Net Income | -52,599 | -17,602 | -7,711 | -11,047 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -35,800 | -14,811 | -5,904 | -12,015 |
Cash | 97,565 | 94,851 | 9,792 | 2,123 |
Basic Shares | 39,217 | 15,271 | 248 | 18 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-09-30 | -$0.31 |
2026-06-30 | -$0.35 |
2026-03-31 | -$0.35 |
2025-12-31 | -$0.38 |